Yesterday, drugmaker Momenta Pharmaceuticals
Waiting for a yet-to-be-determined date for a FDA regulatory decision can maddening, but Momenta and partner Sandoz, a subsidiary of Novartis
Momenta isn't the only drugmaker expecting approval of its generic enoxaparin product. Competitor Watson Pharmaceuticals
Either way, besides advancing the rest of its pipeline forward, including promising second-generation anticoagulant product M118, there's nothing that Momenta can do right now but wait for the FDA decision.
Momenta is a Rule Breakers selection.